193827-69-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its versatile structure allows for the development of new drugs with potential applications in treating a wide range of diseases and conditions.
Used in Antimicrobial Applications:
ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used as an antimicrobial agent for its potential to combat bacterial infections. Its unique chemical structure enables it to target and inhibit the growth of various microorganisms, making it a promising candidate for the development of new antimicrobial drugs.
Used in Antiviral Applications:
In the field of antiviral research, ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used as a potential antiviral agent. Its ability to interfere with viral replication and assembly processes makes it a valuable compound for the development of new antiviral medications.
Used in Antimalarial Applications:
ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used as an antimalarial agent, showing potential in the treatment and prevention of malaria. Its ability to target and disrupt the life cycle of the Plasmodium parasite responsible for malaria makes it a promising candidate for the development of new antimalarial drugs.
Used in Anti-inflammatory Applications:
As an anti-inflammatory agent, ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used to modulate the body's inflammatory response. Its potential to reduce inflammation and alleviate symptoms associated with various inflammatory conditions makes it a valuable compound for the development of new anti-inflammatory medications.
Used in Antitumor Applications:
In the field of oncology, ETHYL 4-CHLORO-6-(TRIFLUOROMETHYL)-3-QUINOLINECARBOXYLATE is used as an antitumor agent. Its potential to inhibit the growth and proliferation of cancer cells, as well as its ability to induce apoptosis, makes it a promising compound for the development of new cancer therapies.

InChI:InChI=1/C13H9ClF3NO2/c1-2-20-12(19)9-6-18-10-4-3-7(13(15,16)17)5-8(10)11(9)14/h3-6H,2H2,1H3

Upstream product

• 26893-12-9 ethyl 4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 49713-39-5 diethyl 2-(((4-(trifluoromethyl)phenyl)amino)methylene)malonate 
• 455-14-1 4-trifluoromethylphenylamine 

Downstream Products

• 206258-00-6 4-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-6-trifluoromethyl-quinoline-3-carboxylic acid ethyl ester 
• 193827-68-8 4-(3-Bromophenylamino)-3-ethoxycarbonyl-6-trifluoromethylquinoline 
• 193827-62-2 3-Ethoxycarbonyl-4-(3-trifluoromethylphenylmercapto)-6-trifluoromethylquinoline 

Relevant academic research and scientific papers

4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation

Mycobacterial DNA gyrase B subunit has been identified to be one of the potentially underexploited drug targets in the field of antitubercular drug discovery. In the present study, we employed structural optimization of the reported GyrB inhibitor resulting in synthesis of a series of 46 novel quinoline derivatives. The compounds were evaluated for their in vitro Mycobacterium smegmatis GyrB inhibitory ability and Mycobacterium tuberculosis DNA supercoiling inhibitory activity. The antitubercular activity of these compounds was tested over Mtb H37Rv strain and their safety profile was checked against mouse macrophage RAW 264.7 cell line. Among all, three compounds (23, 28, and 53) emerged to be active displaying IC50 values below 1 μM against Msm GyrB and were found to be non-cytotoxic at 50 μM concentration. Compound 53 was identified to be potent GyrB inhibitor with 0.86 ± 0.16 μM and an MIC (minimum inhibitory concentration) of 3.3 μM. The binding affinity of this compound towards GyrB protein was analysed by differential scanning fluorimetry which resulted in a positive shift of 3.3 °C in melting temperature (Tm) when compared to the native protein thereby reacertaining the stabilization effect of the compound over protein.

THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and modulating GABAA, and use of the compound of formula I for the treatment

Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC 50's as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1′ group. Select compounds were found to be effective in in vivo models of arthritis.